zopapogene imadenovec
Trade name: Papzimeos
VaccineapprovedOrphan Drug FDA
Approved
Aug 14, 2025
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Mar 16, 2021 (NCT04724980)
Timeline
Indications
Approved for
Mechanism of action
- Human papillomavirusImmunity, active
Human papillomavirus immunity, active
Approval history
- approvedAug 14, 2025
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL6068194 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06538480 | Phase 3 | Jul 11, 2024 | Intrexon |
| NCT04724980 | Phase 1 | Mar 16, 2021 | Intrexon, National Cancer Institute (NCI) |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Intrexon | For profit | 2 | 2 | 2 | 2021 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2021 |
2 organizations
Page 1 / 1